foslevodopa/foscarbidopa vs Rytary (IPX066)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

foslevodopa/foscarbidopa · Vyalev

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT04380142 · Phase 3 · completed

The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).

Reported efficacy

Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)

Result source: NCT04380142

Rytary (IPX066)

Marketed by Amneal Pharmaceuticals

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT00974974 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).

Reported efficacy

Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)

Result source: NCT00974974

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfoslevodopa/​foscarbidopaRytary (IPX066)
OFF time, change-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142—Not reported
ON time without troublesome dyskinesia, change2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142—Not reported
UPDRS Part III, change—Not posted · NCT0437905021.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791
MDS-UPDRS Part II, change-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142—Not reported

OFF time, change

foslevodopa/​foscarbidopa
-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142
Rytary (IPX066)
—Not reported

ON time without troublesome dyskinesia, change

foslevodopa/​foscarbidopa
2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142
Rytary (IPX066)
—Not reported

UPDRS Part III, change

foslevodopa/​foscarbidopa
—Not posted · NCT04379050
Rytary (IPX066)
21.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791

MDS-UPDRS Part II, change

foslevodopa/​foscarbidopa
-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142
Rytary (IPX066)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. foslevodopa/foscarbidopa: 4 of 4 rows · Rytary (IPX066): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfoslevodopa/​foscarbidopaRytary (IPX066)
Dropout rate
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
42.5%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
35.9%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—a
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
24.5%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
20.2%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
17.2%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
8.1%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
22.1%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
17.6%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—a
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
15.3%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
14.4%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
5.7%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
2.6%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Serious AEs
8.1%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
25.8%ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
27.4%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
24.4%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
5.5%a
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
2%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.8%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.6%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
2.3%Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
15.6%Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
25%Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
1.1%
NCT01130493 · Phase 3 · registry result, not featured evidence
7%
NCT01096186 · Phase 3 · registry result, not featured evidence
0%
NCT00869791 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
infusion site erythema 27%
infusion site pain 25.7%
infusion site cellulitis 17.6%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
infusion site erythema 52%
infusion site nodule 28.7%
infusion site oedema 19.3%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
high dose
infusion site erythema 55.8%
infusion site nodule 30.1%
infusion site oedema 24.8%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
low dose
infusion site erythema 48.9%
infusion site nodule 27.5%
infusion site cellulitis 19.1%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
a
insomnia 3.5%
fall 3%
nausea 3%
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
390 mg LD
nausea 20.4% (placebo 8.7%)
headache 17.3% (placebo 10.9%)
dizziness 12.2% (placebo 5.4%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
245 mg LD
dizziness 19.2% (placebo 5.4%)
nausea 19.2% (placebo 8.7%)
headache 12.5% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
145 mg LD
nausea 13.8% (placebo 8.7%)
dizziness 9.2% (placebo 5.4%)
headache 6.9% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
nausea 11.6%
dyskinesia 7%
fall 7%
NCT01411137 · Phase 3 · registry result, not featured evidence
upper respiratory infection 15.6%
anxiety 6.3%
fall 6.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
fall 16.7%
orthostatic hypotension 16.7%
anxiety 8.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
dyskinesia 4.5%
confusional state 3.4%
insomnia 3.4%
NCT01130493 · Phase 3 · registry result, not featured evidence
insomnia 5.8%
dyskinesia 5.5%
fall 5.3%
NCT01096186 · Phase 3 · registry result, not featured evidence
anxiety 3.7%
fatigue 3.7%
feeling of warth in abdomen 3.7%
NCT00869791 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

foslevodopa/foscarbidopa

On" Time Without Troublesome Dyskinesia 2.72 vs 0.97 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
OFF Time -2.75 vs -0.96 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
MDS-UPDRS Part II -2.65 vs -1.06 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
Early Morning "Off 17% (n=47) vs 63.3% (n=60) LD/CD @ 12wk
responder rate · % of participants
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
ON Time Without Dyskinesia 3.13 vs 1.32 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDSS-2 Total -7.92 vs -2.52 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDQ-39 Summary Index -6.38 vs -2.28 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
EQ-5D-5L Summary Index 0.051 vs 0.002 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
OFF Time -2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
-1.84 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.95 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.43 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.36 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.4 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.34 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.43 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.31 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.38 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.35 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.25 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.52 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.37 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.43 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.59 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.51 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time With Troublesome Dyskinesia 0 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
0.11 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.05 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.56 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.23 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.41 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.6 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.38 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.61 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.45 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.49 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.17 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.35 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.64 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.17 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time Without Troublesome Dyskinesia 2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
1.74 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.9 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.99 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.6 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.81 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.1 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.72 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.93 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.92 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.65 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.79 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.74 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.69 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.71 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.08 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.43 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.77 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part I -2.6 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.8 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.4 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.8 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.4 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.3 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

+ 6 further endpoints in the CSV export.

Rytary (IPX066)

Off" Time 23.82% (n=201) vs 29.79% (n=192) IR CD-LD @ 22wk
absolute value · percentage points
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
Off" Time 3.87 vs 4.88 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
3.82 vs 5.22 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
3.83 vs 5.83 IR CD-LD hours @ 1wk
NCT00869791 · Phase 2 · registry result, not featured evidence
On" Time Without Troublesome Dyskinesia 11.84 vs 10.91 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 1 more result
11.36 vs 9.98 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS II III Sum -14.9 vs -0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-12.9 vs -0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-11.7 vs -0.6 placebo score @ 30wk145mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PDQ-39 -6 vs 0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-3.8 vs 0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-4.4 vs 0.6 placebo score @ 30wk145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PGIC 5.2 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.4 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.3 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
CGI-C 5.5 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.7 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.6 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
PDQ-8 9.6 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 3 more results
8.1 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
8.5 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
9 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
Awake OFF Time 23.98% (n=83) vs 32.48% (n=83) CLE @ 2wk
absolute value · percentage points
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 29.3 vs 31.7 CLE score @ 2wk
absolute change · score
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 26.4 score @ 39wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence
UPDRS Total 30.5 score @ 39wk
absolute value · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Rytary (IPX066)'s landscape